Influence of inflammation modulation on excretory mechanisms during intrahepatic cholestasis by Kadová, Zuzana
Abstract 
Charles University in Prague 
Faculty of Pharmacy in Hradec Králové 
Department of Pharmacology and Toxicology 
 
Candidate:   Mgr. Zuzana Kadová 
Supervisor:  Prof. PharmDr. František Štaud, PhD. 
Consultant:  Prof. MUDr. Stanislav Mičuda, PhD. 
 
Title of doctoral thesis: 
Influence of inflammation modulation on excretory mechanisms during 
intrahepatic cholestasis 
Intrahepatic cholestasis accompanies several systemic diseases, and can be induced by 
several drugs. All of its forms are associated with a certain degree of inflammation. The aim of 
this research was therefore to study changes in hepatic and renal elimination pathways during 
different forms of cholestasis, especially endotoxin-induced, and to characterize their 
modulation by administration of currently used or potential anti-inflammatory agents. 
One of the most significant alteration of excretory mechanisms develops during sepsis. 
The status induces acute renal injury through activation of immune response activated by 
lipopolysaccharides (LPS) on their surface. In this study, we examined the possibilities to 
prevent such damage by two potent anti-inflammatory drugs, dexamethasone and anakinra, an 
IL-1 receptor antagonist. Biochemical and molecular signs of renal impairment were observed 
in rats administered the LPS from Salmonellatyphimurium, after pre-treatment with saline, 
dexamethasone or anakinra. In untreated endotoxemic rats characteristic symptoms of renal 
damage appeared within 10 hours - such as reduced glomerular filtration, microalbuminuria 
and reduced tubular secretion of azithromycin, prototype substrate for the transporters Mdr1 
and Mrp2. Pre-treatment by both immunosuppressants alleviated all of these hallmarks typical 
for AKI and returned tubular secretion of azithromycin back to the control level. This effect 
was associated with up-regulation of basolateral transporters for organic anions. Application of 
both substances paradoxically reduced apical Mdr1 and Mrp2 transporters. Furthermore, 
dexamethasone increased renal excretion of bile acid through downregulation of transporter for 
reabsorption, Asbt. Both agents decreased the plasma concentrations of cytokines involved in 
the inflammation and decreased the concentration of NO in response to the reduction of iNOS 
expression in the kidneys and liver. Dexamethasone and anakinra were able to alleviate the 
symptoms of acute kidney injury and modulate changes in expression of transporters involved 
in renal excretion of drugs which were imposed due to administration of endotoxin. In this 
work, we have demonstrated the important role of IL-1 beta in the development of renal 
impairment during sepsis. 
The next step was to elucidate the changes in billiary excretion of drugs during sepsis. 
We evaluated the protective effect of the clinically available iron chelators in the development 
of acute liver injury after administration of endotoxin, where lipopolysaccharide was 
administered, or following pre-treatment with dexrazoxane (DEX) or deferoxamine (DFO). 
Although both compounds reduced the iron content in the liver, only DFO demonstrated a 
protective effect against liver damage. 
Further, we analyzed the potential choleretic effect of boldin, a natural choleretic agent 
in healthy and cholestatic rats. Boldin caused up-regulation of Bsep and increased biliary 
clearance of substrates and bile acids. Furthermore, we described the ability of boldin to 
stimulate FXR, a transcriptional regulator of Bsep. We confirmed this mechanism in the 
following study in which cholestasis was induced by high sucrose diet (HSD) applied to rats 
with hereditary hypertriglyceridemia (HHTg). Boldin alleviated the negative influence of HSD-
induced liver steatosis on the biliary excretion of bile acids and glutathione. The data support 
positive effects of FXR agonists in the therapy of non-alcoholic fatty liver disease. 
 
